Meta-Analyses of Therapies for Postmenopausal Osteoporosis

作者：Osteoporosis Methodology Group · 发表于：Endocrine Reviews · 年份：2002 · DOI：10.1210/edrv.23.4.0486 · 被引用次数：471 · 研究领域：Bone health and osteoporosis research、Estrogen and related hormone effects、Bone Metabolism and Diseases

III. Risedronate Ann Cranney, MD, MSc; Peter Tugwell, MD, MSc; Jonathan Adachi, MD; Bruce Weaver, MSc; Nicole Zytaruk, RN; Alexandra Papaioannou, MD; Vivian Robinson, MSc, Beverley Shea, BScN, MSc; George Wells, PhD; Gordon Guyatt, MD, MSc; the Osteoporosis Methodology Group; and the Osteoporosis Research Advisory Group IV. Raloxifene Ann Cranney, MD, MSc; Peter Tugwell, MD, MSc; Nicole Zytaruk, RN; Vivian Robinson, MSc; Bruce Weaver, MSc; Jonathan Adachi, MD; George Wells, PhD; Beverley Shea, BScN, MSc; Gordon Guyatt, MD, MSc; the Osteoporosis Methodology Group; and the Osteoporosis Research Advisory Group